JERUSALEM, Nov 6 (Reuters) - Teva Pharmaceutical

Industries expects to work productively with the

incoming Trump administration in the United States, chief

executive Richard Francis said on Wednesday.

"Our job, as always, is to work productively with any

administration, and we've shown we can do that, and we will

absolutely do that," Francis told Reuters after the Israeli

drugmaker issued strong third-quarter results.

He said, though, it wouldn't be clear until after Donald

Trump takes office what his healthcare and pharmaceutical

policies will be.

Francis also said that he expects 2025 to be "more of the

same" for the company, with growth in branded drugs, continuing

growth in its generics drugs business, plus more sales of

biosimilars.